Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
| Axogen, Inc.AXGN · Entity 4297 | Chief Executive Officer | February 26, 2026 | February 27, 2026 |
| CVRx, Inc.CVRX · Entity 6920 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 45,133 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 4,942 · Balance 46,342 Row 2 · 2023-03-01 · Sale · Disposed 1,209 · Balance 45,133 |
Axogen, Inc.
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 98,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 98,000 · Balance 98,000 F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F2: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
CVRx, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,005 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 29,005 · Balance 29,005 F1: Vests as to one-third of the shares on each annual anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01 | Direct | 36,252 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 36,252 · Balance 36,252 F1: Vests as to one-third of the shares on each annual anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests as to one-third of the shares on each annual anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 22:03 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 36,252 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001172346-26-000004 · form4-06032026_100618.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,252 Underlying: Common Stock · 36,252 shares Expires 2036-06-01 F1 · derivative.exercise_date: Vests as to one-third of the shares on each annual anniversary of the date of grant. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:03 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantCommon Stock | 29,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001172346-26-000004 · form4-06032026_100618.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,005 F1 · shares: Vests as to one-third of the shares on each annual anniversary of the date of grant. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:20 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 98,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000036 · wk-form4_1772227199.xml · derivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:06 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 25,000 | $30.00 | $750,000.00 |
DisclosureSEC source: 0000805928-25-000171 · wk-form4_1765573574.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,537 Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 22:21 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 61,463 | $31.21 | $1,918,137.30 |
DisclosureSEC source: 0000805928-25-000167 · wk-form4_1765405262.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,537 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units on December 4, 2025. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on December 9, 2025, in multiple transactions at $31.208 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000145 · wk-form4_1764968812.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 F1 · shares: This reflects the number of shares that vested as of December 4, 2025 upon the attainment of certain performance criteria. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 20:48 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 176,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000046 · wk-form4_1743022084.xml · derivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,300 Underlying: Common Stock · 176,300 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| August 09, 2024 Filed Aug 9, 2024 20:20 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantPerformance Stock Units · Derivative | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-094782 · ownership.xml · derivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three year performance period beginning February 22, 2024 and ending February 22, 2027. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person. The number of PSUs earned could range from 0% to 200% of such target number. The PSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the reporting person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4) F1 · derivative.exercise_date: Each performance stock unit ("PSU") represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three year performance period beginning February 22, 2024 and ending February 22, 2027. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person. The number of PSUs earned could range from 0% to 200% of such target number. The PSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the reporting person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4) F1 · derivative.expiration_date: Each performance stock unit ("PSU") represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three year performance period beginning February 22, 2024 and ending February 22, 2027. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person. The number of PSUs earned could range from 0% to 200% of such target number. The PSUs were granted pursuant to an inducement award agreement outside of the Issuer's Amended and Restated 2019 Long-Term Incentive Plan as a material inducement to the reporting person's acceptance of employment with the Issuer in accordance with NASDAQ Listing Rule 5635(c)(4) Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,209 | $100.70 | $121,746.30 |
DisclosureSEC source: 0001415889-23-003899 · form4-03032023_120339.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,133 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,942 | $99.77 | $493,063.34 |
DisclosureSEC source: 0001415889-23-003899 · form4-03032023_120339.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,342 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 37,483 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003049 · form4-02222023_110249.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,483 Underlying: Common Shares · 37,483 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003049 · form4-02222023_110249.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,284 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,000 | $117.00 | $468,001.20 |
DisclosureSEC source: 0001415889-22-002844 · form4-03102022_020344.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,780 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,053 | $118.15 | $124,412.27 |
DisclosureSEC source: 0001415889-22-002189 · form4-03022022_040327.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,780 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,505 | $122.41 | $551,457.05 |
DisclosureSEC source: 0001415889-22-002189 · form4-03022022_040327.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,833 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 54,280 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001733 · form4-02232022_050253.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,280 Underlying: Common Shares · 54,280 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001733 · form4-02232022_050253.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,338 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,600 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001415889-21-003748 · form4-07302021_020718.xml · derivative · entry 3 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,600 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 17,600 | $120.33 | $2,117,881.92 |
DisclosureSEC source: 0001415889-21-003748 · form4-07302021_020718.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,691 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.3203 to $120.35, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,600 | $50.72 | $892,672.00 |
DisclosureSEC source: 0001415889-21-003748 · form4-07302021_020718.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 00:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,475 | $120.61 | $177,899.75 |
DisclosureSEC source: 0001415889-21-001200 · form4-03022021_040334.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,691 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,000 | $121.58 | $486,320.00 |
DisclosureSEC source: 0001415889-21-001200 · form4-03022021_040334.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,166 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 53,326 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000888 · form4-02232021_030249.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,326 Underlying: Common Shares · 53,326 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,775 on February 19, 2022, 17,775 on February 19, 2023, and 17,776 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000888 · form4-02232021_030249.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,166 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 787 | $77.89 | $61,299.43 |
DisclosureSEC source: 0001179110-20-002902 · edgar.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,763 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,147 | $79.19 | $170,020.93 |
DisclosureSEC source: 0001179110-20-002902 · edgar.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,550 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOptions (right to buy) · Derivative | 83,818 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002289 · edgar.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,818 Underlying: Common shares · 83,818 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,939 on February 21, 2021, 27,939 on February 21, 2022, and 27,940 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommons shares without par value | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002289 · edgar.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,697 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 396 | $88.97 | $35,232.12 |
DisclosureSEC source: 0001179110-20-001896 · edgar.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,947 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 951 | $89.66 | $85,266.66 |
DisclosureSEC source: 0001179110-20-001896 · edgar.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,343 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.